ArticleFrontiers in nutrition2026
Gastrointestinal symptoms and the Mediterranean dietary pattern: secondary analysis of a randomized controlled trial in a population with increased cardiometabolic risk.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/objectives: Cardiometabolic diseases are a major global health concern, and their development are linked to suboptimal dietary patterns and adverse gastrointestinal (GI) health outcomes and symptoms. Mediterranean dietary patterns are associated with reduced cardiometabolic disease risk and improved quality of life (QoL). The potential impact of the Mediterranean diet on GI symptoms is an important area of inquiry that requires elucidation. This study aimed to evaluate whether a New Zealand-adapted Mediterranean diet (NZMedDiet) affects GI symptom severity in adults at increased cardiometabolic risk, explore the influence of participant characteristics on symptoms, and assess the association between GI symptoms and health-related QoL. Methods: This secondary analysis used data from a randomized controlled trial of a 12-week NZMedDiet and behavioral intervention in adults with increased cardiometabolic risk. Associations were assessed between the gastrointestinal symptom rating scale (GSRS), the 36-Item Short-Form Survey (SF-36)(assessing QoL), and the NZMedDiet, alongside participant characteristics. Results: A total of 200 participants were enrolled (mean age 49.9 ± 10.9 years; 62% women), with women reporting significantly higher baseline GI symptom severity scores on average across all GSRS domains except reflux ( Conclusion: The NZMedDiet had a positive impact on GI symptom severity scores and was well tolerated in participants with increased cardiometabolic risk. Improvements in GSRS domains were correlated with moderate improvements in QoL measurements. Clinical trial registration: https://www.anzctr.org.au/Default.aspx, identifier ACTRN12622000906752 and https://www.isrctn.com/, identifier ISRCTN89011056.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.